Belite Bio, Inc (BLTE): Price and Financial Metrics
BLTE Price/Volume Stats
| Current price | $82.53 | 52-week high | $86.53 |
| Prev. close | $82.34 | 52-week low | $31.00 |
| Day low | $81.51 | Volume | 59,600 |
| Day high | $83.50 | Avg. volume | 55,257 |
| 50-day MA | $61.25 | Dividend yield | N/A |
| 200-day MA | $49.39 | Market Cap | 2.53B |
BLTE Stock Price Chart Interactive Chart >
Belite Bio, Inc (BLTE) Company Bio
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Price Returns
| 1-mo | 37.66% |
| 3-mo | 68.74% |
| 6-mo | 81.11% |
| 1-year | 118.97% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 80.39% |
| 2023 | 51.77% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...